1. Growth differentiation factor 11 delivered by dairy Lactococcus lactis strains modulates inflammation and prevents mucosal damage in a mice model of intestinal mucositis
- Author
-
Monique Ferrary Américo, Andria dos Santos Freitas, Tales Fernando da Silva, Luís Cláudio Lima de Jesus, Fernanda Alvarenga Lima Barroso, Gabriela Munis Campos, Rhayane Cristina Viegas Santos, Gabriel Camargos Gomes, Rafael Assis, Ênio Ferreira, Pamela Mancha-Agresti, Juliana Guimarães Laguna, Jean-Marc Chatel, Rodrigo Dias de Oliveira Carvalho, and Vasco Azevedo
- Subjects
intestinal inflammation ,5-fluorouracil ,lactic acid bacteria ,DNA delivery ,gene therapy ,Microbiology ,QR1-502 - Abstract
Mucositis is an inflammation of the gastrointestinal mucosa that debilitate the quality of life of patients undergoing chemotherapy treatments. In this context, antineoplastic drugs, such as 5-fluorouracil, provokes ulcerations in the intestinal mucosa that lead to the secretion of pro-inflammatory cytokines by activating the NF-κB pathway. Alternative approaches to treat the disease using probiotic strains show promising results, and thereafter, treatments that target the site of inflammation could be further explored. Recently, studies reported that the protein GDF11 has an anti-inflammatory role in several diseases, including in vitro and in vivo results in different experimental models. Hence, this study evaluated the anti-inflammatory effect of GDF11 delivered by Lactococcus lactis strains NCDO2118 and MG1363 in a murine model of intestinal mucositis induced by 5-FU. Our results showed that mice treated with the recombinant lactococci strains presented improved histopathological scores of intestinal damage and a reduction of goblet cell degeneration in the mucosa. It was also observed a significant reduction of neutrophil infiltration in the tissue in comparison to positive control group. Moreover, we observed immunomodulation of inflammatory markers Nfkb1, Nlrp3, Tnf, and upregulation of Il10 in mRNA expression levels in groups treated with recombinant strains that help to partially explain the ameliorative effect in the mucosa. Therefore, the results found in this study suggest that the use of recombinant L. lactis (pExu:gdf11) could offer a potential gene therapy for intestinal mucositis induced by 5-FU.
- Published
- 2023
- Full Text
- View/download PDF